The aim of this study was to determine the prevalence of T helper 9 (Th9) lymphocytes in rheumatoid arthritis (RA) patients and to identify a possible association between the percentage of Th9 and the discontinuation of a biological treatment with an anti-tumor necrosis factor (TNF) (infliximab). We collected peripheral blood mononuclear cells (PBMCs) from 55 consecutive RA outpatients and 10 healthy controls. Among RA patients, 15 were not receiving any immunosuppressive drug, 20 were successfully treated with infliximab and 20 discontinued infliximab because of adverse events or inefficacy and were treated with other biological agents. PBMCs were cultured with/without infliximab 50 mg/L for 18 h, and the percentage of Th9 cells was assessed by means of flow cytometry. Th9 lymphocytes were identified as interferon gamma, interleukin (IL)4-, IL17-, IL9-secreting cluster of differentiation 4 (CD4)+ T cells. Cytometric analysis revealed no significant decrease in the percentage of Th9 cells after infliximab exposure in any of the groups, although it was lower in healthy controls than RA patients either before and after the infliximab stimulation assay. Th9 cells are IL-9-secreting T helper lymphocytes whose role in RA is still poorly known. IL-9 levels are increased in RA patients, in whom this cytokine plays a crucial role. Th9 cells are the major producers of IL-9, and their prevalence is higher in RA patients than in healthy subjects; however our experiment in vitro does not demonstrate an association between Th9 lymphocytes and the response to infliximab. Further studies are required to evaluate the real involvement of Th9 population in the immunogenicity of anti-TNF agents.
n INTRODUCTION R heumatoid arthritis (RA) is a chronic autoimmune disease affecting up to 1% of worldwide population with a progressively disabling course. RA is characterized by chronic synovitis of peripheral joints, mainly ruled by the uncontrolled activation of cells belonging to the adaptive immunity. Cluster of differentiation 4 (CD4)+ T lymphocytes play a central role in the induction and in the maintenance of the disease, due to their complex interplay with dendritic cells, macrophages, and B-lymphocytes. According to the cytokine milieu, CD4+ T lymphocytes may differentiate Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients ulation (lectin from Phytolacca americana; 1 μg/mL; Sigma-Aldrich, St. Louis, MO, USA) was used as a positive control to evaluate the responsiveness of PBMCs. To facilitate co-stimulation, 1 μg/mL anti-human CD28 (R&D Systems) was added to the cell cultures. Brefeldin A (10 μg/mL; Sigma-Aldrich) was added after the first three hours in order to inhibit cytokine secretion. The percentage of Th9 lymphocytes was determined by flow cytometric analysis. Th9 lymphocytes were identified as IFNγ-, IL-4-, IL-17-, IL-9 secreting CD4+ T cells (6). A concentration of infliximab of 50 μg/mL was chosen after setting a titration test with increasing concentrations of the drug and on the basis of the infliximab median serum concentrations one hour after infusion (peak serum concentration: 39.9-219.1 μg/mL) (7). The following monoclonal antibodies (mAbs) were used: CD4 PE-Cy7, IFNγ (Beckman Coulter, Milan, Italy), IL17 PerCP-Cy5.5 (Biolegend, San Diego, CA, USA), IL-9 APC and IL-4 PE (R&D Systems). PBMCs were incubated 15 minutes with the mAbs for the detection of cell surface antigens and fixed with 1% paraformaldehyde (PFA). Then cells were permeabilized with Saponin (Sigma) and stained with the antibodies for the detection of intracellular cytokines. Following a 45-minute incubation in ice, the cells were fixed with 1% PFA. Lymphocyte population was gated based on the basis of forward and side scatter properties, and further gated for CD4 expression; at least 20,000 events were acquired within the CD4 gate. The samples were acquired using a Gallios flow cytometer and data were analysed using Kaluza software (both Beckman Coulter). As data were normally distributed, procedures were based on parametric analyses. Comparisons between the different groups were performed using unpaired Student's t test for unequal variances with a two tailed P value. Significance was set at P<0.05. Statistical analysis was performed using GraphPad Prism Software (GraphPad Software, San Diego, CA, USA). (11, 12) . A consistent number of reports has evidenced that these cells are highly represented in the airways of asthmatic subjects as well as in the skin of people suffering from atopic dermatitis (13, 14) . Recent reports on melanoma tumor models have evidenced that Th9 lymphocytes enhance the intra-tumor expression of chemokines and their receptors such as CCL20 and CCR6, thus promoting the recruitment of dendritic cells and anti-tumor CD8+ T lymphocytes (15) . The role of Th9 cells in rheumatic diseases is less characterized. According to some (18) . In the gut, Th9 cells are involved in the defence against parasitic infections and an increase in this T helper subset may represent a link between dysbiosis and autoimmune inflammatory bowel diseases (11) . One study on connective tissue diseases reported that IL-9 serum levels were increased in systemic sclerosis but not in systemic lupus erythematosus or dermatomyositis, being inversely correlated with the degree of lung fibrosis (19) . This result may be interpreted in the light of the pleiotropic effects of IL-9, promoting at the same time the expansion of Treg and Th17 lymphocytes ( Figure  2 ) (20) . To our knowledge, there are actually few studies on the involvement of IL-9 in RA. One study analysed by multiple suspension array the serum cytokine profile of 6 RA patients undergoing rituximab treatment after failing a previous therapy line with infliximab. The authors found increased levels of IL-9 at baseline and at follow-up times in responder patients and concluded that IL-9 may be considered as a predictive marker of response to rituximab (21) . Another study on 44 subjects showed an increased serum concentration of IL-9 in first-degree relatives of RA patients, which was associated to a higher ratio of auto-antibodies positivity, such as RF or ACPAs (22) . A recent report on RA, psoriatic arthritis (PsA) and osteoarthritis (OA) patients showed an augmented concentration of IL-9 in blood and synovial fluid of RA and PsA subjects than in OA ones. Furthermore the treatment of magnetically sorted synovial and blood CD3+ T cells with recombinant IL-9 induced their expansion only in RA and PsA samples, underlining the hyper-expression of IL-9R on cells coming from patients suffering from autoimmune arthritis (23) . Finally, a recent histological study on synovial membrane biopsies from RA patients evidenced an augmented expression of Th9 lymphocytes in the most aggressive forms of disease and an association between these cells and the organisation of the lymphoid centres or the synthesis of ACPAs (3). In line with these data, our results showed an increased percentage of Th9 cells in the peripheral blood of RA patients when compared to healthy controls, but no difference was noticed before and after the incubation of PBMCs in vitro with infliximab. A limit of the study was that we did not sorted Th9 lymphocytes according to the specific transcriptional factor profile (PU.1 or IRF-4), perhaps including other T CD4+ subsets in the pool of Th9 producing cells. However, these data may also reflect the bipolar effects of these cells, favoring at the same time the survival and the activation of Th17 and Treg lymphocytes. Due to their ambivalent behavior, Th9 cells would be therefore not suitable for predicting the response or the failure to a specific treatment in RA patients. Figure 2 resumes the complexity of the role of Th9 cells played in the immune network.
n CONCLUSIONS
In conclusion, IL-9 levels are increased in RA patients. Th9 cells are the major producers of IL-9, and their amount is higher in RA patients than in healthy subjects; however our experiment in vitro does not demonstrate an association between Th9 lymphocytes and the response to infliximab. IL-9 producing cells restore a balance between tolerance and inflammation and, according to our results, cannot be considered a reliable marker in predicting the response to anti-TNF agents. However our study has some limits and the actual knowledge about the biologic effects of these cells in RA is still incomplete and requires further investigations.
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